BRYCE RICHARD PAUL 4
4 · PUMA BIOTECHNOLOGY, INC. · Filed Oct 5, 2020
Insider Transaction Report
Form 4
BRYCE RICHARD PAUL
SR VP, CLINICAL RESEARCH & DEV
Transactions
- Sale
COMMON STOCK
2020-10-02$10.14/sh−91$923→ 76,816 total
Footnotes (1)
- [F1]The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units.